From Domain Specific Biology to COAs: Advancing Endpoints for Cognition & Impulsivity

• Progress in developing novel clinical outcome assessments targeting specific domains such as cognition in schizophrenia and impulsivity in bipolar disorder
• Using scalable, crowdsourced behavioral tasks with large normative datasets to strengthen translational relevance and signal detection
• Lessons learned from early regulatory interactions on qualifying new endpoints and defining their context of use
• Why cross industry collaboration is critical to gaining acceptance and adoption of new psychiatric endpoints across trials and populations

Speakers:

James Cronican

Head Vice President, Experimental Medicine Neuroscience & Mental Health

Boehringer Ingelheim